Centura Health recognized with HIMSS Davies Award

HIMSS North America has awarded Centura Health with a 2015 HIMSS Enterprise Davies Award, which recognizes outstanding achievement of organizations that have utilized health IT to substantially improve patient outcomes while achieving return on investment.

The Davies Awards program promotes EHR-enabled improvement in patient outcomes through sharing of case studies and lessons learned across a wide range of efforts, including implementation strategies, workflow design, best practice development and adherence, and patient engagement that have improved both financial and care outcomes.

Centura Health was founded in 1996 by Catholic Health Initiatives and Adventist Health System, and manages 16 hospitals in Colorado and Kansas ranging from geographically remote, 30-bed hospitals, to a Level One Trauma Center with 220 beds in a metropolitan area with a population of more than 2.5 million supporting over 90,000 inpatient admissions and over 1 million outpatient physician and clinic visits per year.

Focused on improving population health outcomes, Centura Health has been able to significantly reduce hospitalizations associated with chronic disease management using alternative payment models enabled with risk stratification, clinical decision support, patient engagement and analytics, according to a release. Within the remote Durango, Colo. community, Mercy Family Medicine reduced the hospital admission rate for each 1,000 admissions for Ambulatory Care Sensitive Conditions, which includes angina, asthma, chronic obstructive pulmonary disease [COPD], diabetes, grand mal status and other epileptic convulsions, heart failure and pulmonary edema and hypertension, by 27 percent. Across the Centura Health system, the use of a Medicare Shared Savings styled ACO model of care resulted in reductions of 15.65 percent in readmission for heart failure, and 7.4 percent for the overall annual per member cost of care.

Centura Health will be recognized at the 2016 Annual HIMSS Conference & Exhibition in February in Las Vegas.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.